OncoMatch/Clinical Trials/NCT06091124
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
Is NCT06091124 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Adebrelimab and Etoposide for neuroendocrine carcinoma of the bladder.
Treatment: Adebrelimab · Etoposide · Cisplatin — The goal of this clinical trial is to learn about the efficacy and safety of neoadjuvant adebrelimab plus etoposide and cisplatin in patients with neuroendocrine bladder carcinoma. The main questions it aims to answer are: * The pathologic complete response rate at radical cystectomy * Safety and tolerability of combination therapy Participants will be treated with a combination therapy of adebrelimab, etoposide, and cisplatin before radical cystectomy, with a maximum of 4 cycles.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Urothelial Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy.
Cannot have received: anti-PD-L1 therapy
Prior anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy.
Cannot have received: anti-CTLA-4 therapy
Prior anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy.
Cannot have received: systemic drug therapy for cancer
Exception: Intravesical chemotherapy or immunotherapy ended at least 1 week before the start of study.
Prior drug therapy for cancer, except: Intravesical chemotherapy or immunotherapy ended at least 1 week before the start of study.
Cannot have received: radiotherapy for bladder cancer
Prior radiotherapy for bladder cancer.
Cannot have received: other antitumor therapy or immunomodulatory therapy (including corticosteroid therapy, immunotherapy)
Participants who have received other antitumor therapy or immunomodulatory therapy (including corticosteroid therapy, immunotherapy) or participated in other clinical studies within 4 weeks before the start of study treatment, or have not recovered from previous toxicity (except for 2 degree alopecia and 1 degree neurotoxicity).
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
Cannot have received: solid organ transplantation
Prior allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
Lab requirements
Blood counts
hb≥90 g/l; anc≥1.5×109 /l; plt≥100×109 /l
Kidney function
serum creatinine ≤2×uln, or endogenous creatinine clearance > 20 ml /min (cockcroft-gault formula)
Liver function
t-bil≤1.5×uln; alt and ast≤2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify